Evidence map›Paper›PMID 39292730›Full record

ArticlePloS one2024

The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: A cross-sectional study.

Archana Koirala, Jocelynne McRae, Philip N Britton, Marnie Downes, Shayal A Prasad, Suellen Nicholson, Noni E Winkler, Matthew V N O'Sullivan, Fatima Gondalwala, Cecile Castellano and 35 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors.

Archana KoiralaNational Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia.ORCID 0000-0002-2567-8825
Jocelynne McRaeFaculty of Medicine and Health, University of Sydney's Hospital Westmead Clinical School, Westmead, NSW, Australia.
Philip N BrittonFaculty of Medicine and Health, University of Sydney's Hospital Westmead Clinical School, Westmead, NSW, Australia.ORCID 0000-0002-2993-6000
Marnie DownesClinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Parkville, VIC, Australia.
Shayal A PrasadNational Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia.
Suellen NicholsonInfectious Diseases Serology, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital at The Doherty Institute, Melbourne, VIC, Australia.ORCID 0000-0001-6585-7150
Noni E WinklerNational Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia.
Matthew V N O'SullivanInstitute of Clinical Pathology and Medical Research, New South Wales Pathology, Westmead, Australia.
Fatima GondalwalaNational Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia.
Cecile CastellanoNational Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia.
Emma CareyNational Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia.
Alexandra HendryNational Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia.
Nigel CrawfordInfection, Immunity & Global Health, Murdoch Children's Research Institute, Parkville, VIC, Australia.
Ushma WadiaWesfarmers Centre of Vaccine and Infectious Diseases, Telethon Kids Institute, Nedlands, WA, Australia.
Peter RichmondWesfarmers Centre of Vaccine and Infectious Diseases, Telethon Kids Institute, Nedlands, WA, Australia.
Helen S MarshallFaculty of Health and Medical Sciences, The University of Adelaide, Adelaid, SA, Australia.
Julia E ClarkInfection Management, Children's Health Queensland, Brisbane, QLD, Australia.
Joshua R FrancisGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Tiwi, NT, Australia.
Jeremy CarrDepartment of Infection and Immunity, Monash Children's Hospital Melbourne, Clayton, VIC, Australia.
Adam BartlettDepartment of Immunology and Infectious Diseases, Sydney Children's Hospital, Randwick, NSW, Australia.ORCID 0000-0002-7532-9316
Brendan McMullanDepartment of Immunology and Infectious Diseases, Sydney Children's Hospital, Randwick, NSW, Australia.
Justin SkownoDepartment of Anaesthesia, The Children's Hospital at Westmead, Westmead, NSW, Australia.
Donald HannahDepartment of Anaesthesia, The Children's Hospital at Westmead, Westmead, NSW, Australia.
Andrew DavidsonMelbourne Children's Trials Centre, Murdoch Children's Research Institute, Parkville, VIC, Australia.
Britta S von Ungern-SternbergDepartment of Anaesthesia and Pain Medicine, Perth Children's Hospital, Nedland, WA, Australia.
Paul Lee-ArcherDepartment of Anaesthesia, Queensland Children's Hospital, South Brisbane, QLD, Australia.
Laura L BurgoyneDepartment of Children's Anaesthesia, Women's and Children's Hospital, North Adelaide, SA, Australia.
Edith B WaughDepartment of Anaesthesia and Perioperative Medicine, Royal Darwin Hospital, NT, Australia.ORCID 0000-0002-8685-5389
John B CarlinClinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Parkville, VIC, Australia.
Zin NaingSerology and Virology Division (SAViD), Department of Microbiology, NSW Health Pathology East, Prince of Wales Hospital, Randwick, NSW, Australia.
Nicole KerlyDepartment of Immunology and Infectious Diseases, Sydney Children's Hospital, Randwick, NSW, Australia.
Alissa McMinnSurveillance of Adverse Events Following Vaccination In the Community (SAFEVIC), Murdoch Children's Research Institute, Parkville, Victoria, Australia.
Guillian HunterDepartment of Infection and Immunity, Monash Children's Hospital Melbourne, Clayton, VIC, Australia.
Christine HeathUniversity Department of Paediatrics, Women's and Children's Hospital, North Adelaide, SA, Australia.
Natascha D'AngeloUniversity Department of Paediatrics, Women's and Children's Hospital, North Adelaide, SA, Australia.
Carolyn FinucaneInfectious Disease Epidemiology, Telethon Kids Institute, Nedlands, WA, Australia.
Laura A FrancisDepartment of Paediatrics, Royal Darwin Hospital, Tiwi, NT, Australia.
Sonia DoughertyInfectious Diseases Research, Children's Health Queensland, South Brisbane, QLD, Australia.
William RawlinsonSerology and Virology Division (SAViD), Department of Microbiology, NSW Health Pathology East, Prince of Wales Hospital, Randwick, NSW, Australia.
Theo KarapanagiotidisInfectious Diseases Serology, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital at The Doherty Institute, Melbourne, VIC, Australia.
Natalie CainInfectious Diseases Serology, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital at The Doherty Institute, Melbourne, VIC, Australia.
Rianne BrizuelaInfectious Diseases Serology, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital at The Doherty Institute, Melbourne, VIC, Australia.
Christopher C BlythWesfarmers Centre of Vaccine and Infectious Diseases, Telethon Kids Institute, Nedlands, WA, Australia.
Nicholas WoodNational Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia.
Kristine MacartneyNational Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia.ORCID 0000-0002-4675-0232

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFollowing reduction of public health and social measures concurrent with SARS-CoV-2 Omicron emergence in late 2021 in Australia, COVID-19 case notification rates rose rapidly. As rates of direct viral testing and reporting dropped, true infection rates were most likely to be underestimated.

objectiveTo better understand infection rates and immunity in this population, we aimed to estimate SARS-CoV-2 seroprevalence in Australians aged 0-19 years.

methodsWe conducted a national cross sectional serosurvey from June 1, 2022, to August 31, 2022, in children aged 0-19 years undergoing an anesthetic procedure at eight tertiary pediatric hospitals. Participant questionnaires were administered, and blood samples tested using the Roche Elecsys Anti-SARS-CoV-2 total spike and nucleocapsid antibody assays. Spike and nucleocapsid seroprevalence adjusted for geographic and socioeconomic imbalances in the participant sample compared to the Australian population was estimated using multilevel regression and poststratification within a Bayesian framework.

resultsBlood was collected from 2,046 participants (median age: 6.6 years). The overall adjusted seroprevalence of spike-antibody was 92.1% (95% credible interval (CrI) 91.0-93.3%) and nucleocapsid-antibody was 67.0% (95% CrI 64.6-69.3). In unvaccinated children spike and nucleocapsid antibody seroprevalences were 84.2% (95% CrI 81.9-86.5) and 67.1% (95%CrI 64.0-69.8), respectively. Seroprevalence was similar across geographic remoteness index and socioeconomic quintiles. Nucleocapsid antibody seroprevalence increased with age while the point seroprevalence of the spike antibody seroprevalence decreased in the first year of life and then increased to 97.8 (95% Crl 96.1-99.2) by 12-15 years of age.

conclusionMost Australian children and adolescents aged 0-19 years, across all jurisdictions were infected with SARS-CoV-2 by August 2022, suggesting rapid and uniform spread across the population in a very short time period. High seropositivity in unvaccinated children informed COVID-19 vaccine recommendations in Australia.

Indexed as

Antibodies, ViralCOVID-19SARS-CoV-2AdolescentAustraliaChildChild, PreschoolCross-Sectional StudiesFemaleHumansInfantInfant, NewbornMaleSeroepidemiologic StudiesSpike Glycoprotein, CoronavirusYoung AdultAntibodies, ViralSpike Glycoprotein, Coronavirus

Identifiers

PMID39292730
PMCPMC11410239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.